CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug your doctor prescribed.

As evidence has mounted that new diabetes and weight loss drugs can provide a variety of health benefits, the FDA has approved Novo Nordisk’s semaglutide for heart disease and Eli Lilly’s ...

Shares of Eli Lilly & Co. were headed for their worst day in nearly four years on Tuesday after the drugmaker provided a fourth-quarter revenue outlook that was below expectations, citing slower ...

Shelby Knowles / Bloomberg via Getty Images Eli Lilly's Zepbound can be covered by Medicare Part D plans after the FDA approved the drug as a treatment for sleep apnea last month. Weight loss ...

Eli Lilly (LLY) Stock Price Prediction in 2025 The current Wall Street consensus 1-year price target of Eli Lilly stock is $1030.00, which is 36.07% higher than today’s price of $756.99.

This result is comparable to Eli Lilly's Phase 3 SURMOUNT-1 trial of tirzepatide, which showed up to a 22.5% weight loss at the same time point. Although Novo Nordisk has not released detailed ...

The firm also notes that, based on historical data, tirzepatide has shown better tolerability when compared cross-trial to the lower 2.4 mg dose of semaglutide. In Eli Lilly's SURMOUNT-1 trial ...

In the ongoing quest to expand semaglutide’s clinical pedigree ... constant competition with its metabolic medicine rival Eli Lilly, which markets counterparts to Ozempic and Wegovy in the ...

Eli Lilly (NYSE ... is the main competition for Lilly's Mounjaro. Novo's obesity drug, Wegovy, is the top rival to Lilly's Zepbound. Semaglutide, the active ingredient in Ozempic and Wegovy ...

Shares of Eli Lilly have been falling in recent months, but that could spell opportunity. Investors appear to be concerned that a new government could impact its growth potential. The business is ...